Study Title
Dose-escalation Study of BAY1129980 (NCT02134197)
Trial Description
The purpose of this study is to evaluate:
- The side effects of BAY1129980 when given every 21 days different dose levels.
- Determine the dose level of BAY1129980 that should be tested in future clinical research studies.
- Measure how much BAY1129980 is in the blood at specific times after administration.
- If treatment with BAY1129980 shows any effect on reducing the tumor growth.
- If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not.
- If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).
This trial is sponsored by Bayer®
Study Data
- Condition: Neoplasms
- Interventions:
- Drugs used in this trial
- BAY1129980
- Drugs used in this trial
- Phase: I
- Estimated Enrollment: 60
- Start: May 2014
- Estimated Completion: December 2018
- Last verified:September 2017
- Last updated: September 2017
Study Schematic
Click here to Return to Drug map
Last Editorial review: September 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
